Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?

HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons

(2015) Pedro Guedes-Dias et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A phase I study of resminostat in Japanese patients with advanced solid tumors

(2015) Satoru Kitazono et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors

(2015) Rob De Vreese et al.   CHEMICAL COMMUNICATIONS

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors

(2015) Marina Savelieva et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit

(2015) Charles M. Marson et al.   JOURNAL OF MEDICINAL CHEMISTRY

ApoE4 and A  Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation

(2015) A. Sen et al.   JOURNAL OF NEUROSCIENCE

Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue

(2015) Gavin Rumbaugh et al.   NEUROPSYCHOPHARMACOLOGY

Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease

(2015) Shraddha R. Bang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor

(2015) Loredana Vesci et al.   Oncotarget

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

(2014) Edwin Choy et al.   CANCER

Is there new hope for therapeutic matrix metalloproteinase inhibition?

(2014) Roosmarijn E. Vandenbroucke et al.   NATURE REVIEWS DRUG DISCOVERY

Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

(2014) Maj-Linda Selenica et al.   Alzheimers Research & Therapy

Vorinostat-induced bone loss might be related to drug toxicity

(2013) Song Xu et al.   BONE

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

(2013) Guido Finazzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

(2013) B. Venugopal et al.   CLINICAL CANCER RESEARCH

Histone-deacetylase inhibitors produce positive results in the GADD45a-GFP GreenScreen HC assay

(2013) Donna Johnson et al.   MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

(2013) Mercedes Lobera et al.   Nature Chemical Biology

Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability

(2013) Jeanine Jochems et al.   NEUROPSYCHOPHARMACOLOGY

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

(2013) Alexandra P. Zorzi et al.   PEDIATRIC BLOOD & CANCER

HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner

(2013) M. Malvaez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tropolones As Lead-Like Natural Products: The Development of Potent and Selective Histone Deacetylase Inhibitors

(2013) Sophia N. Ononye et al.   ACS Medicinal Chemistry Letters

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Chiral Mercaptoacetamides Display Enantioselective Inhibition of Histone Deacetylase 6 and Exhibit Neuroprotection in Cortical Neuron Models of Oxidative Stress

(2012) Jay H. Kalin et al.   ChemMedChem

Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease

(2012) Nambirajan Govindarajan et al.   EMBO Molecular Medicine

Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

(2012) You Me Sung et al.   EXPERIMENTAL NEUROLOGY

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial

(2012) Toshihiko Doi et al.   International Journal of Clinical Oncology

Metal-assisted Lossen Rearrangement

(2012) Lucie Jašíková et al.   JOURNAL OF ORGANIC CHEMISTRY

HDAC6 Inhibitor Blocks Amyloid Beta-Induced Impairment of Mitochondrial Transport in Hippocampal Neurons

(2012) Chaeyoung Kim et al.   PLoS One

Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors

(2011) Lewis Whitehead et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

(2011) Paul Hamberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease

(2011) Constantin d'Ydewalle et al.   NATURE MEDICINE

Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse Model

(2010) Myriam Rai et al.   PLoS One

Targeting the correct HDAC(s) to treat cognitive disorders

(2010) André Fischer et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Base-mediated rearrangement of free aromatic hydroxamic acids (ArCO–NHOH) to anilines

(2009) Yujiro Hoshino et al.   CHEMICAL COMMUNICATIONS

The Interaction of Zinc(II) and Hydroxamic Acids and a Metal-Triggered Lossen Rearrangement

(2009) Lucie Ducháčková et al.   CHEMISTRY-A EUROPEAN JOURNAL

Studies of Benzamide- and Thiol-Based Histone Deacetylase Inhibitors in Models of Oxidative-Stress-Induced Neuronal Death: Identification of Some HDAC3-Selective Inhibitors

(2009) Yufeng Chen et al.   ChemMedChem

Nonclinical Safety Assessment of the Histone Deacetylase Inhibitor Vorinostat

(2009) Janet S. Kerr et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY

Identification of Novel, Selective, and Stable Inhibitors of Class II Histone Deacetylases. Validation Studies of the Inhibition of the Enzymatic Activity of HDAC4 by Small Molecules as a Novel Approach for Cancer Therapy

(2009) Jesus M. Ontoria et al.   JOURNAL OF MEDICINAL CHEMISTRY

Carbonyldiimidazole-Mediated Lossen Rearrangement

(2009) Pascal Dubé et al.   ORGANIC LETTERS

Structural Studies of Human Histone Deacetylase 8 and Its Site-Specific Variants Complexed with Substrate and Inhibitors†,‡

(2008) Daniel P. Dowling et al.   BIOCHEMISTRY

Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC Inhibitors—Nanomolar-Potency Inhibitors of Pancreatic Cancer Cell Growth

(2008) Alan P. Kozikowski et al.   ChemMedChem

Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor

(2008) Yongcheng Ying et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY